Top Markets
#1 Tutorial Tutorial +32.13%
#2 Official Trump Official Trump +30.85%
#3 Siacoin Siacoin +22.77%
#4 EXOD EXOD +22.08%
#5 Mubarak Mubarak +20.56%
#6 MowCat MowCat +18.58%
#7 Wrapped STX (Velar) Wrapped STX (Velar) +18.51%
#8 Unit Pump Unit Pump +17.74%
#9 Pump.fun Pump.fun +17.74%
#10 Melania Meme Melania Meme +16.61%
Coin of the day
Tutorial Tutorial
Tetapan
Bahasa
MALAY
Mata wang
USD
Tema
GlycoNex Incorporation GlycoNex Incorporation

GlycoNex Incorporation

4168
Kedudukan dalam Saham #22943
GlycoNex Incorporation, based in New Taipei City, Taiwan, specializes in... GlycoNex Incorporation, based in New Taipei City, Taiwan, specializes in developing innovative cancer therapeutics. The company achieves this by leveraging advanced glycosphingolipid antigen and human monoclonal antibody technologies. Its robust pipeline for solid tumors features several investigational antibody drugs. These include GNX102, a humanized monoclonal antibody currently in Phase 1 clinical trials; GNX201, an antibody candidate undergoing lead optimization; and GNX202, which is in preclinical development. Additionally, GNX203 and GNX204 are antibody drugs presently in the target validation stage. Beyond oncology, GlycoNex is also advancing other therapeutic agents. This includes SPD (Denosumab), a humanized IgG2 antibody in preclinical stages for both osteoporosis and oncology indications. Another key asset is SEA (Aflibercept), a vascular endothelial growth factor (VEGF) binding fusion protein, currently undergoing lead optimization for its potential use in ophthalmology and oncology. GlycoNex was established in 2001.
Harga Saham
$0.71865803
Disegerakkan terakhir: 2026-08-21
Modal Pasaran
$80.86M
Perubahan (1 hari)
0.00%
Perubahan (1 tahun)
-5.48%
Negara
TW
Perdagangan GlycoNex Incorporation (4168)

Kategori

Healthcare
Nisbah P/E bagi GlycoNex Incorporation (4168)
Nisbah P/E pada 2026 TTM: 0
Menurut laporan kewangan dan harga saham terkini GlycoNex Incorporation, nisbah P/E semasa (TTM) ialah 0. Pada akhir 2026, syarikat mempunyai nisbah P/E sebanyak 0.
Sejarah nisbah P/E bagi GlycoNex Incorporation dari 2026 hingga 2026
Nisbah P/E pada akhir setiap tahun
Tahun Nisbah P/E Ubah
Tidak cukup data untuk tarikh yang disediakan.
Nisbah P/E untuk syarikat serupa atau pesaing
Syarikat Nisbah P/E Perbezaan Nisbah P/E Negara
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 29.20 -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 30.62 -
NL
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 -7.93 -
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
 32.46 -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Cara membaca nisbah P/E

Nisbah Harga/Perolehan (P/E) mengukur hubungan antara harga saham syarikat dan pendapatan sesaham.
P/E yang rendah tetapi positif menunjukkan syarikat menjana keuntungan tinggi berbanding dengan penilaian semasa dan mungkin dinilai rendah. P/E negatif yang tinggi (hampir 0) menunjukkan kerugian besar.

Syarikat dengan P/E melebihi 30 atau negatif biasanya dilihat sebagai "saham pertumbuhan", bermaksud pelabur menjangkakan pertumbuhan atau keuntungan masa depan.

Syarikat dengan P/E positif di bawah 10 biasanya dianggap sebagai "saham nilai", bermaksud syarikat sudah menguntungkan dan tidak dijangka berkembang pesat.